MedTrace Logo

Prazosin for Agitation in Alzheimer's Disease

NCT03710642 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2023-02-06

Study results available
· View outcomes & findings →

Summary

The study evaluates the effects of Prazosin on agitation in adults with Alzheimer's disease.

Two thirds of the participants will participate in the medication portion, while one third will participate in the placebo portion

Conditions

Interventions

DRUG

Prazosin

Oral prazosin HCl capsules (or placebo) will be administered twice daily, with individualized doses up to a maximum of 4 mg QAM mid-morning and 6 mg at bedtime (QHS), or matching placebo capsules

DRUG

Placebo oral capsule

Placebo capsule matched to appearance of active drug.

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • VA Puget Sound Health Care System

    collaborator FED

  • Alzheimer's Association

    collaborator OTHER

  • Alzheimer's Disease Cooperative Study (ADCS)

    lead OTHER

Principal Investigators

  • Howard Feldman · Alzheimer's Disease Cooperative Study (ADCS)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-23
Primary Completion
2022-01-05
Completion
2022-01-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03710642 on ClinicalTrials.gov